Preview

Онкоурология

Расширенный поиск

МОЛЕКУЛЯРНЫЕ МАРКЕРЫ РАКА МОЧЕВОГО ПУЗЫРЯ: ОТ ЧАСТНОГО К ЦЕЛОМУ

https://doi.org/10.17650/1726-9776-2011-7-3-16-19

Полный текст:

Аннотация

Рак мочевого пузыря (РМП) занимает 2-е место по распространенности среди злокачественных опухолей мочеполовой системы. Ранняя диагностика РМП, как правило, существенно повышает вероятность успешного лечения пациента. В статье рассмотрены методы неинвазивной диагностики РМП и приводится база данных известных молекулярных маркеров этого заболевания.

Об авторах

А. А. Заболотнева
Институт биоорганической химии им. акад. М.М. Шемякина и Ю.А. Овчинникова РАН, Москва
Россия


Н. М. Гайфуллин
Факультет фундаментальной медицины МГУ им. М.В. Ломоносова
Россия


А. А. Буздин
Институт биоорганической химии им. акад. М.М. Шемякина и Ю.А. Овчинникова РАН, Москва
Россия


Б. Я. Алексеев
МНИОИ им. П.А. Герцена
Россия


Ю. Ю. Андреева
МНИОИ им. П.А. Герцена
Россия


П. В. Шегай
МНИОИ им. П.А. Герцена
Россия


Д. Г. Соков
Московский городской онкологический диспансер
Россия


И. Г. Русаков
МНИОИ им. П.А. Герцена
Россия


Список литературы

1. Parkin D.M., Bray F., Ferlay J. et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55(2):74–108.

2. Ploeg M., Aben K.K., Kiemeney L.A. The present and future burden of urinary bladder cancer in the world. World J Urol 2009; 27(3):289–93.

3. Jacobs B.L., Lee C.T, Montie J.E. Bladder cancer in 2010: how far have we come? CA Cancer J Clin 2010;60(4):244–72.

4. Kaufman D.S., Shipley W.U., Feldman A.S. Bladder cancer. Lancet 2009; 374(9685):239–49.

5. O' Donoghue P.M., McSweeney S.E., Jhaveri K. Genitourinary imaging: current and emerging applications. J Postgrad Med 2010;56(2):131–9.

6. Qu X., Huang X., Wu L. et al. Comparison of virtual cystoscopy and ultrasonography for bladder cancer detection: A meta-analysis. Eur J Radiol 2010.

7. Sanchez-Carbayo M. Use of high-throughput DNA microarrays to identify biomarkers for bladder cancer. Clin Chem 2003;49(1):23–31.

8. Junttila T.T., Laato M., Vahlberg T. et al. Identification of patients with transitional cell carcinoma of the bladder overexpressing ErbB2, ErbB3, or specific ErbB4 isoforms: real-time reverse transcription-PCR analysis in estimation of ErbB receptor status from cancer patients. Clin Cancer Res 2003;9(14):5346–57.

9. Yang Y.C., Li X., Chen W. Characterization of genes associated with different phenotypes of human bladder cancer cells. Acta Biochim Biophys Sin (Shanghai) 2006;38(9):602–10.

10. Kenney D.M., Geschwindt R.D., Kary M.R. et al. Detection of newly diagnosed bladder cancer, bladder cancer recurrence and bladder cancer in patients with hematuria using quantitative rt-PCR of urinary survivin. Tumour Biol 2007; 28(2):57–62.

11. Van Tilborg A.A., Bangma C.H., Zwarthoff E.C. Bladder cancer biomarkers and their role in surveillance and screening. Int J Urol 2009; 16(1):23–30.

12. Eissa S., Swellam M., Ali-Labib R. et al. Detection of telomerase in urine by 3 methods: evaluation of diagnostic accuracy for bladder cancer. J Urol 2007;178(3 Pt 1):1068–72.

13. Christoph F., Muller M., Schostak M. et al. Quantitative detection of cytokeratin 20 mRNA expression in bladder carcinoma by real-time reverse transcriptase-polymerase chain reaction. Urology 2004;64(1):157–61.

14. Carrington J.C., Ambros V. Role of microRNAs in plant and animal development. Science 2003;301(5631):336–8.

15. Dyrskjot L., Ostenfeld M.S., Bramsen J.B. et al. Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res 2009;69(11):4851–60.

16. Kawamoto K., Enokida H., Gotanda T. et al. p16INK4a and p14ARF methylation as a potential biomarker for human bladder cancer. Biochem Biophys Res Commun 2006;339(3):790–6.

17. Tada Y., Wada M., Taguchi K. et al. The association of death-associated protein kinase hypermethylation with early recurrence in superficial bladder cancers. Cancer Res 2002;62(14):4048–53.

18. Friedrich M.G., S. Chandrasoma K.D. Siegmund et al. Prognostic relevance of methylation markers in patients with non-muscle invasive bladder carcinoma. Eur J Cancer 2005;41(17):2769–78.

19. Marsit C.J., Houseman E.A., Schned A.R. et al. Promoter hypermethylation is associated with current smoking, age, gender and survival in bladder cancer. Carcinogenesis 2007; 28(8):1745–51.

20. Sarosdy M.F., Schellhammer P., Bokinsky G. et al. Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol 2002;168(5):1950–4.

21. Knowles M.A. Molecular pathogenesis of bladder cancer. Int J Clin Oncol 2008; 13(4):287–97.

22. Van Rhijn B.W., Lurkin I., Kirkels W.J. et al. Microsatellite analysis–DNA test in urine competes with cystoscopy in follow-up of superficial bladder carcinoma: a phase II trial. Cancer 2001;92(4):768–75.

23. Zhang J., Fan Z., Gao Y. et al. Detecting bladder cancer in the Chinese by microsatellite analysis: ethnic and etiologic considerations. J Natl Cancer Inst 2001;93(1):45–50.

24. Goode E.L., Ulrich C.M., Potter J.D. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev 2002; 11(12):1513–30.

25. Marsh H.P., Haldar N.A., Bunce M. et al. Polymorphisms in tumour necrosis factor (TNF) are associated with risk of bladder cancer and grade of tumour at presentation. Br J Cancer 2003;89(6):1096–101.

26. Liotta L.A., Petricoin E.F. Serum peptidome for cancer detection: spinning biologic trash into diagnostic gold. J Clin Invest 2006;116(1):26–30.

27. Babjuk M., Soukup V., Pesl M. et al. Urinary cytology and quantitative BTA and UBC tests in surveillance of patients with pTapT1 bladder urothelial carcinoma. Urology 2008;71(4):718–22.

28. Fernandez-Gomez J., Rodriguez-Martinez J.J., Barmadah S.E. et al. Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer. Eur Urol 2007;51(5):1267–74.

29. Lodde M., Mian C., Comploj E. et al. uCyt+ test: alternative to cystoscopy for lessinvasive follow-up of patients with low risk of urothelial carcinoma. Urology 2006;67(5):950–4.

30. Miyanaga N., Akaza H., Tsukamoto S. et al. Usefulness of urinary NMP22 to detect tumor recurrence of superficial bladder cancer after transurethral resection. Int J Clin Oncol 2003;8(6):369–73.


Для цитирования:


Заболотнева А.А., Гайфуллин Н.М., Буздин А.А., Алексеев Б.Я., Андреева Ю.Ю., Шегай П.В., Соков Д.Г., Русаков И.Г. МОЛЕКУЛЯРНЫЕ МАРКЕРЫ РАКА МОЧЕВОГО ПУЗЫРЯ: ОТ ЧАСТНОГО К ЦЕЛОМУ. Онкоурология. 2011;7(3):16-19. https://doi.org/10.17650/1726-9776-2011-7-3-16-19

For citation:


Zabolotneva A.A., Gaifullin N.M., Buzdin A.A., Alekseyev B.Y., Andreyeva Y.Y., Shegai P.V., Sokov D.G., Rusakov I.G. MOLECULAR MARKERS OF BLADDER CANCER: FROM THE PARTICULAR TO THE GENERAL. Cancer Urology. 2011;7(3):16-19. (In Russ.) https://doi.org/10.17650/1726-9776-2011-7-3-16-19

Просмотров: 324


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1726-9776 (Print)
ISSN 1996-1812 (Online)